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Clinical trials are experiments tested on human to compare the effect of certain inter-
vention. Any intervention has to be tested in different phases of clinical trials. In early-stage
(phase 0, I, and II) trials, fewer number of patients are enrolled to get preliminary informa-
tion on safety and efficacy. In late-stage (phase III and IV) trials, larger number of patients
are randomized to further confirm the efficacy and safety. The purpose of each phase may
change depending on the therapeutic area and patient characteristics.
In Chapter 2, we propose a family of designs for phase I oncology trials. In these trials,
oncologists assign different patients at a varying range of dose levels to find the dose that
gives the highest acceptable rate of dose-limiting toxicities, which will be the recommended
dose for phase II trials. In current practice, most such trials are rule-based designs that
determine whether to escalate the dose using data from the current dose only. The 3+3
design is the most popular rule-based design. Our proposed design, which we denote the
cohort-sequence design, addresses the deficiencies of the 3+3 design, while preserving its
simplicity. We compare the proposed design with the 3+3 using simulation studies.
Late-stage randomized clinical trials might lack external validity when there are treatment-
by-covariate interactions involving factors whose distribution in the population differ from
that in the trial. In Chapter 3, we project the results from a trial to a population using post-
stratification, and compare it with other approaches that use probabilities of trial inclusion.
We use intention-to-treat estimate of the treatment effect, which compares the difference in
average responses in assigned experimental treatment versus control groups. We demonstrate
v
this using data from Lipids Research Clinics Coronary Primary Prevention Trial.
The intention-to-treat analysis focuses on the treatment effect of randomization on the
outcome, without considering compliance. In Chapter 4, we extend the interpolation ap-
proaches using instrumental variables estimation of the complier average causal effect, which
is the treatment effect on the outcome restricted to the subset of subjects who adhere to
assigned treatment. We apply these methods to the data from Lipids Research Clinics Coro-
nary Primary Prevention Trial and New York School Choice Experiment.
vi
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Clinical trials are experiments tested on human beings to compare the effect and safety of
intervention against a control. Any new treatment needs to pass different phases of clinical
trials before being allowed to go into market. Phase 0 studies are proof-of-principle, studying
pharmacokinetic and pharmacodynamic of an intervention. Oncology phase I trials are for
dose-finding and getting preliminary information on safety. Phase II trials obtain further
information on efficacy and safety. Phase III trials involve a large number of patients ran-
domized to compare the experimental intervention with control, or standard-of-care. Phase
IV trials monitor safety efficacy for the post-marking product. The purpose of each phase
may vary based on the therapeutic area and diseased population.
In this dissertation, one chapter is focused on phase I dose-finding designs. The other
two chapters are aiming to project the results from a randomized clinical trial to a target
diseased population.
1.2. Flexible, rule-based dose escalation: The cohort-sequence design
Phase I oncology trials obtain preliminary information on the safety of novel treatments.
Most trials employ rule-based designs with pre-specified escalation/de-escalation rules based
on observed number of toxicities from the current dose. The objective is to identify the
1
maximum tolerated dose (MTD)— the highest dose with rate of dose-limiting toxicities
below a pre-specified threshold. The 3+3 design is the most common rule-based design
largely due to its simplicity, (28) but it has several deficiencies. First, the design is inflexible
for different toxicity threshold. (22) Second, the design is not efficient, with most patients
assigned at low doses with little therapeutic benefits. Third, the number of patients treated
at the maximum tolerated dose is 6, so it will obtain limited information.
In Chapter 2, we devise a family of rule-based dose-finding design that avoids the problem
of the 3+3, while preserving its simplicity. Our design, which we called the cohort-sequence
design, involves a sequence of cohort sizes and corresponding critical values for dose-limiting
toxicities. It improves the efficiency by enrolling more patients around doses that are likely to
be the maximum tolerated dose. We use simulation studies to compare the cohort-sequence
design with the 3+3 design.
1.3. Projecting clinical trial results to a target population
In randomized trials, the results lack external validity if there are treatment-by-covariate
interactions involving factors that are represented differently from the target population. If
information on the covariates in the target population is available, and the treatment effect
is similar across subgroups in the trial and target population, then one can interpolate the
treatment effect to the target population.
One interpolation approach is post-stratification, or re-weighting of subgroup estimates
based on the covariate distribution in the target population. This approach does not require
individual level data for the target population, and works well with few number of con-
founders. We use dataset from Lipids Research Clinics Coronary Primary Prevention Trial
to demonstrate post-stratification, (30) and compare it with two other approaches using trial
inclusion probabilities. (38, 48)
2
1.4. Projecting instrumental variable results to a target population
The intention-to-treat analysis is commonly used for measuring the treatment effect.
This as-randomized analysis does not consider compliance. In Chapter 4, we extend these
interpolation analyses to instrumental variables estimation of the complier average causal
effect (CACE), which is the treatment effect on the outcome among patients who adhere to
the treatment.
We use the Lipids Research Clinics Coronary Primary Prevention Trial, measuring com-
pliance as the fraction of assigned packets taken. (30) In addition, we use data from New
York School Choice Experiment, which is a randomized encouragement to study the effect
of private school voucher on improvement in test scores. (5, 18) We use both randomization
assignment and actual attendance of private school for estimating the CACE.
3
CHAPTER 2
FLEXIBLE, RULE-BASED DOSE ESCALATION: THE COHORT-SEQUENCE DESIGN
2.1. Introduction
Oncologists acquire preliminary information on the safety of a novel treatment through
the conduct of a phase I trial. Whereas statisticians commonly formulate the objective of
such a trial as the identification of the treatment’s maximum tolerated dose (MTD) — that
is, the dose that gives the highest acceptable rate of dose-limiting toxicities (DLTs). The
typical design calls for enrolling subjects in dose cohorts, starting from a low dose that is
believed to be safe and increasing after each cohort until encountering a designated level of
toxicity.
Most phase I trials employ rule-based designs that use data from only the current cohort
to decide what the next step will be. The most popular such design is the 3+3, a variant
of the up-and-down rule.(6, 13, 24, 25, 28, 54) Some alternatives to the 3+3 include the
A+B design,(54) which generalizes the cohort sizes in the 3+3; the accelerated titration
design, which starts with one-patient cohorts and reverts to the 3+3 plan once toxicities
appear;(46) and the toxicity probability interval (TPI) and modified TPI (mTPI) designs,
which use Bayesian criteria to select the next dose.(23, 24, 25) Yet despite the availability
of these and other alternative designs, many with excellent statistical properties, as recently
as 2009 nearly 97% of phase I trials used the 3+3.(28)
The 3+3 design is simple and familiar but has notable deficiencies: First, for commonly
encountered toxicity profiles, the 3+3 most often selects doses with DLT rates in the range
4
20%–25%, well below the typical nominal target of 30%–35%.(22) Second, most patients
in a 3+3 trial receive doses that have low rates of both toxicity and therapeutic effect; a
more efficient design would escalate quickly past these to reach doses that are of greater
interest. Third, the maximum number of patients that a 3+3 enrolls at the final dose is
6, implying that it will obtain only limited information about toxicity and efficacy at the
purported MTD. Thus it has become common to augment the phase I trial with a dose-
expansion cohort — an additional group of patients who receive treatment at the identified
MTD. Often, the choice of sample size for this additional cohorts is arbitrary,(32) and in any
event the benefits of an expansion cohort are limited if the trial can potentially mis-estimate
the MTD.
An alternative is the model-based design, in which one assumes an underlying parametric
dose-response model and uses the accumulated data to estimate parameters and, thereby,
the MTD.(4, 6, 9, 19, 28, 39, 41, 51) Some pharmaceutical companies now use such designs
routinely, often in “bucket” trials or phase I/II designs. The large majority of phase I
cancer trials, however, continue to employ rule-based designs, primarily the 3+3.(31) This
reluctance to adopt the newer methods may reflect several factors: The substantial cost
and complexity of implementing the model-based methods; lack of familiarity with them; or
simply a conviction that “better is the enemy of good enough”. (34)
The objective in this chapter is to devise a rule-based dose-finding design that avoids the
problems of the 3+3 while preserving, to the extent possible, its simplicity. The method,
which we denote the cohort-sequence design, permits tuning of the cohort sizes and critical
values to reflect the targeted DLT rate. It improves efficiency by focusing enrollment at
doses where toxicities are likely to occur, thereby creating larger cohorts in the vicinity of
the MTD and obviating the need to append an arbitrarily sized dose-expansion cohort.
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2.2. Methods
2.2.1. Escalation plan for the cohort-sequence design
The cohort-sequence design consists of a sequence of cohort sizes n = (n1, . . . , nJ) and
corresponding DLT critical values b = (b1, . . . , bJ) that indicate whether to escalate, de-
escalate, or add more subjects at the current dose. The notion is to begin with a small cohort
size n1 and escalate through the planned series of increasing doses D = (D1, . . . , Dm), raising
the cohort size as we begin to encounter toxicities. Specifically, when enrolling subjects at
dose Di with cohort size nj, the decision to escalate, add more at the current dose, or de-
escalate hinges on whether the observed number of DLTs in the cohort falls below, equals,
or exceeds the corresponding critical value bj. If the number of DLTs at dose Di exceeds
bj, we stop treating the cohort at that dose to avoid excessive toxicities. A possible value
for the sequence of cohort sizes would be n = (1, 3, 5, 8, 10), with corresponding sequence of
critical values b = (1, 2, 3, 4, 5).
Figure 2.1 displays the flow chart for our design. Suppose that the current dose level is
Di and that our current cohort size is nj with corresponding critical value bj. We enroll up
to nj subjects at this dose and observe the number of DLTs as Xi. If Xi < bj, we deem the
current dose to be safe, and we escalate and enroll the next cohort at dose Di+1 with the
same cohort size nj and critical value bj. If Xi > bj, we deem the current dose unsafe, and
we enroll the next cohort at the next lower dose Di−1 with the terminal cohort size nJ and
corresponding critical value bJ . If Xi = bj, we deem the current dose as potentially, but not
certainly, toxic, and we increase the cohort size to nj+1 and the corresponding critical value
to bj+1, enrolling additional subjects at this dose until the cohort is filled and we can again
evaluate the safety data. The escalation/de-escalation continues in this way until a safe dose
is achieved (Xi < bJ) after a de-escalation, or the trial de-escalates to the lowest dose. If we
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escalate to the highest dose Dm with cohort size nj, and observe Xm < bj, then we increase
the cohort size to nJ and the critical value to bJ . We estimate the MTD as the highest safe
dose evaluated. Alternatively, one can specify a total number of patients and stop when all
have received treatment, again identifying the highest safe dose as the MTD.
Figure 2.1. Flow chart for the cohort-sequence design.
2.2.2. Identification of the critical value for a designated cohort size
We select the pairs (nj, bj), j = 1, . . . , J to represent a comparable level of certainty
about the DLT rate at the given dose. That is, for each nj, the selected bj is one that
identifies the current dose as safe, unsafe, or indeterminate, by a criterion that is common
across cohort sizes. To accomplish this, we first select a safety threshold, denoted θ ∈ (0, 1).
The principle is that if we are reasonably sure that the DLT rate at dose Di is below θ,
we escalate; if we are reasonably sure that the DLT rate at Di exceeds θ, we de-escalate;
otherwise, we collect more data at Di. Having chosen θ, we can either compute the critical
value bj from a selected cohort size nj, or vice versa.
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We first demonstrate the computation of bj from nj. We evaluate uncertainty about the
toxicity level using Bayesian posterior probabilities. At dose level Di, the number of DLTs
Xi is binomial with parameters (Ni, τi), where Ni and τi = τ(Di) represent the cohort size
and toxicity probability, respectively. We assume a Beta(1,4) prior for τi, which updates to
Beta(1 +Xi, 4 +Ni−Xi) after Xi DLTs in Ni trials. We use this prior because it represents
the situation where there are X = 0 events in a previous N = 3 patients starting from a
uniform prior, which approximates the level of uncertainty that one would express before
examining an untested dose level. As in the TPI and mTPI designs,(23, 24, 25) we use the
same prior for all dose levels because we have essentially no prior data at any dose level.
Starting from a fixed nj, to determine the critical level bj we compute the posterior
probability that τi exceeds the safety threshold θ, which we denote
f(Xi, Ni, θ) ≡ Pr[τi > θ|Xi, Ni].
We fix a threshold of 10% for this posterior probability. For example, if f(Xi, Ni, θ) is below
10%, then we deem the dose level safe for escalation. If f(Xi, Ni, θ) is well above 10%, we de-
escalate. If f(Xi, Ni, θ) is above 10% but f(Xi−1, Ni, θ) is below 10%, we collect more data
at the current dose. We select bj by identifying the value of Xi such that f(Xi, Ni, θ) > 10%
and f(Xi − 1, Ni, θ) ≤ 10%.
2.2.3. Identification of the cohort size for a designated critical value
Alternatively, one can select a sequence of bj values and then calculate the corresponding
cohort sizes nj. To avoid ambiguities, the bj values should constitute an increasing sequence;
b = (1, 2, . . . , J) is a natural choice. We start by computing f(bj − 1, x, θ) for x ≥ bj, which
decreases as x increases. Then nj is the smallest x such that f(bj − 1, x, θ) ≤ 10%, and
f(bj, x, θ) > 10%. Figure 2.2 illustrates the process of identifying the cohort size.
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Figure 2.2. Flow chart for determining the cohort size based on specified DLTs (X), under
safety threshold θ.
2.2.4. Selection of the number of cohort sizes
The final element of the design is the number of cohort sizes, which we denote J . As
a rule, for a fixed bj, the smaller the value of θ, the larger will be the corresponding nj.
Therefore, for small values of θ it is preferable to choose a smaller J ; otherwise, the total
sample size of the cohort may be excessive. In the next subsection we demonstrate some
feasible choices of θ and J .
2.2.5. Example designs
Flexibility of the design derives from the safety threshold θ. We note that one should
think of θ as a tuning parameter and not a target DLT rate; in simulations (see Section 2.3
below), we show that θ typically exceeds the modal DLT rate by 10%–20%. For example,
θ = 0.25 leads to a low maximum DLT rate; θ = 0.35 to a moderate rate; and θ = 0.50 to a
high rate. Thus a strategy for identifying a design is to simulate frequency properties under
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a likely dose-response curve for a range of values of θ and J , selecting the pair that gives the
desired target DLT rate with a feasible sample size.
We use the notation CS(100θ;n1, . . . , nJ) to denote a cohort-sequence design using θ as
the toxicity threshold and n1, . . . , nJ as the sequence of cohort sizes, assuming by default
that b = (1, 2, . . . , J). For cohort-sequence designs with high maximum acceptable DLT
rate we set J = 5 and θ = 0.5, which leads to cohort sizes n = (1, 3, 5, 8, 10). We denote
this design CS(50;1,3,5,8,10), or henceforth CS(50). For moderate maximum acceptable
DLT rate, we set J = 2 and θ = 0.35 and derive n = (2, 6), designated CS(35;2,6). For
low maximum acceptable DLT rate, we set θ = 0.25 and J = 2 and compute n = (5, 11),
designated CS(25;5,11). Alternatively, letting θ = 0.4 and b = (1, 2, 3), the cohort sizes are
n = (3, 6, 9), which is similar to the 3+3 with an expansion cohort of size 3; we designate
this design CS(40;3,6,9). We present these n, b combinations in Table 2.1.
Table 2.1. Decision rules for cohort-sequence designs used in the simulation.
Sequence of cohort sizes (n)
DLT limit (bj) CS(25;5,11) CS(35;2,6) CS(40;3,6,9) CS(50)
1 5 2 3 1




With J > 5 or θ < 0.3, the possible total number of subjects in the study can exceed the
sample sizes that are typical for phase I trials. On the other hand, with J < 5, one may not
achieve the numbers of subjects at the candidate MTD that we typically observe in practice
when θ is large. With J = 5, the cohort size at the identified MTD is similar to the sizes of
typical dose-expansion cohorts, making it unnecessary to enroll additional patients at those
doses.
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We have implemented the cohort-sequence design in the R package cohortsequence, which
computes f(Xi, Ni, θ) and can calculate bj from nj and vice versa. The package also provides




Ahn conducted simulations to compare the 3+3 with variants of the model-based contin-
ual reassessment method (CRM) design. (2) We used the same dose/toxicity scenarios as in
his paper, comparing cohort-sequence designs for θ ∈ {0.25, 0.35, 0.4, 0.5}. Our simulations
terminated cohorts as soon as the number of DLTs was high enough to signal toxicity, a
practice that improves efficiency and eliminates inadmissible toxicity.
We compared the performance of seven dose-escalation designs:
1. The traditional 3+3.
2. The 3+3 with an expansion cohort of size 3, with the stopping bound for safety in the
expansion cohort set to 2;(32) we denote this design as 3+3@9,2. With this design, we
de-escalate from an unsafe expansion cohort and enroll another until the final dose is
safe.
3. CS(40;3,6,9): A cohort-sequence design that is similar to the 3+3@9,2.
4. CS(25;5,11): Suitable for a low target DLT rate.
5. CS(35;2,6): Suitable for a moderate target DLT rate.
6. CS(50;1,3,5): Suitable for a higher target DLT rate with fewer patients.
11
7. CS(50): Suitable for a higher target DLT and including a built-in expansion cohort.
We repeated the simulation 5000 times. When the lowest dose was rejected as toxic,
the estimated MTD was designated as dose level 0. In this case, the number of patients
treated at the estimated MTD is 0, and we do not enroll an expansion cohort. We used
various frequency measures to compare performance: The proportion of times each dose was
recommended as the MTD, the fraction of patients treated at each dose, the average number
of patients enrolled, and the average proportion of patients experiencing a DLT.
2.3.2. Results
Tables 2.2–2.5 display simulated frequency properties of the designs applied to Ahn’s
scenarios. When the target toxicity is ≤ 10%, the CS(25;5,11) design gives the correct
estimate most frequently. When the target toxicity is between 10% and 25%, the prediction
accuracy for CS(35) is higher. When the target toxicity exceeds 25%, designs with θ = 0.5
lead to correct estimates most often. Cohort-sequence designs generally treat lower fractions
of subjects at low, safe doses. An exception is the CS(40;3,6,9), which closely mimics the
behavior of 3+3.
The 3+3@9,2 and CS(40;3,6,9) designs require 4 to 6 more patients than the traditional
3+3, with the extra patients constituting a built-in dose-expansion cohort. For cohort-
sequence designs with θ = 0.5, the average number of patients with J = 3 is smaller than
with J = 5, although other frequency properties are similar. The CS(50;1,3,5) in particular
requires fewer patients than the 3+3. CS(35;2,6) performs similarly to 3+3 in terms of MTD
recommendation and patient allocation, but it requires 3 fewer patients in toxicity scenario
4 and 1 fewer patient in the other scenarios.
With a higher value of the tuning parameter θ, the realized toxicity fraction is typically
higher. Yet even for the CS(50) designs, which deliberately target higher toxicity rates,
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the fractions of subjects experiencing toxicity are less than 35% under all 4 scenarios. The
toxicity percentages for the traditional 3+3 design are similar to those for CS(35;2,6) and
CS(40;3,6,9).
CS(50) designs, with their greater tolerance for DLTs, assign more patients at higher
dose levels. Nevertheless, they effectively avoid extremely toxic doses, as subjects rarely
reach dose levels with DLT rates in excess of 50%. The CS(25;5,11) design enrolls subjects
at these highly toxic doses only in scenarios 3 and 4, where there is a steep jump from 25%
DLTs to 80% DLTs in one dose elevation. Even so, it enrolls fewer subjects at those levels
than the 3+3 and 3+3-like cohort-sequence designs.
2.4. Application
It is generally impossible to compare designs on a “live” data set, because any real data
would have arisen under a design that dictated a sequence of dose assignments that another
design would not replicate. To attempt a realistic comparison of designs, we generated
DLT responses using a probit model estimated from the data of Simon et al.(46) The model
assumes Yi = log(di) + i with i ∼ N(0, σ2), and registers a DLT if Yi > K. We estimated
the parameters to be σ = 1.092 and K = 8.78, which lead to DLT probabilities of 1%,
5%, 14%, 32%, and 56% at doses 11, 13, 15, 17, and 19, respectively. For each subject, we
generated a normal error i and created a corresponding latent outcome under each dose di.
In this way we created an ensemble of correlated data sets, one for each design.
Results appear in Table 2.6. All the methods estimate the MTD as either dose 15
(DLT rate 14%) or dose 17 (DLT rate 32%). The 3+3 with no expansion cohort yields a
moderate sample size, a small fraction of DLTs, and the lowest proportion of subjects at or
near the ultimate MTD. The 3+3@9,2 and the similar CS(40;3,6,9) give identical results;
compared to the 3+3, they have larger sample sizes, comparable fractions of DLTs, and
larger proportions of subjects treated at or near the MTD. CS(35;2,6) and CS(50) give equal
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or larger proportions of DLTs than the 3+3-type designs, but also treat more patients at or
near the estimated MTD. Notably, both CS(50) and CS(50;1,3,5) enroll fewer subjects and
estimate the MTD as dose 17. CS(40;3,6,9) has a low DLT proportion comparable to that
of the 3+3 design, but treats a larger fraction of subjects near the estimated MTD. These
advantages come at the expense of a larger sample size.
2.5. DISCUSSION
We have proposed a family of rule-based phase I designs that retains the simplicity of
the 3+3 while addressing its inflexibility and inefficiency.
We note that we have examined our design only in conventional scenarios where toxicity
rates increase — sometimes slowly, sometimes quickly — with increasing doses. Some con-
temporary cancer treatments, such as immunotherapies, have toxicity curves that are not
strictly monotonic. In such a case, one may wish to use a method that aims to optimize
response subject to a maximum acceptable toxicity. From the standpoint of a statistician
tasked with designing a trial whose main objective is to study safety, the key consideration
must be to identify, and pull back from, toxic doses. We therefore believe that there is a
continuing role for traditional designs that operate on this principle, even in trials where
there is a strong prior expectation of a non-monotone toxicity curve.
Unlike the 3+3, which targets DLT rates in the range 20%–25%, with our approach
one can select a design to reflect any targeted DLT rate by means of the tuning parameter
θ. Simulations suggest that choosing θ to be 10%–20% higher than the target toxicity
probability gives the best chance of having the target dose be the modal dose, although this
varies by scenario. The choice of J , the maximum number of cohort sizes, largely controls
the total number of patients enrolled. If the sample size available for the trial is comparable
to those typically in use with 3+3 designs, then J = 2 works well for lower target toxicity
rates, whereas J ∈ {3, 4, 5} works well for target toxicity rates of 25% or higher. When
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the target toxicity is between 10% and 25%, CS(35;2,6) is a practical choice. When the
target toxicity exceeds 25%, we recommend CS(50;1,3,5) for a smaller total sample size or
CS(50;1,3,5,8,10) when more patients are available. Using a large final cohort increases
sample size requirements but eliminates the need for an add-on dose-expansion cohort.
Our cohort-sequence design improves efficiency by escalating rapidly through the lower,
safer doses and increasing cohort sizes adaptively when one begins to encounter toxicities.
Consequently, it generally enrolls more patients in the vicinity of the estimated MTD and
incurs higher overall DLT rates. This is an advantage of the cohort-sequence approach, which
avoids the wasteful assignment of subjects to doses that are likely to be safe and ineffective.
In this way the cohort-sequence design paints a clearer picture of the drug’s toxicity profile
and increases the chance of clinical responses.
Our design effectively generalizes the 3+3; the CS(40;3,6,9) version is comparable to
the 3+3@9,2, which is a 3+3 with added dose-expansion cohort. Unsurprisingly, these two
designs and the 3+3 perform comparably on most metrics, except that the 3+3 enrolls fewer
patients because it lacks a built-in expansion cohort. The CS(35;2,6) also performs similarly
to the 3+3, with slightly fewer patients.
Although the critical values of the cohort-sequence design reflect Bayesian notions of
parameter uncertainty, unlike the model-based designs it estimates the MTD based only on
information from patients treated at the identified MTD. An alternative, hybrid approach
that uses all the data would be to run the study with a rule-based design and then estimate a
model (such as the logistic) for the dose-response data, designating as MTD the dose whose
predicted DLT rate is closest to, but does not exceed, the target rate.
Model-based designs such as the CRM aim to identify the dose that delivers a targeted
DLT rate. (39) By assuming an underlying dose-response model, all the data come into play
at every decision point. These designs are both accurate and efficient, provided only that
the assumed model is roughly correct. Their shortcomings are twofold: First, there is the
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need to specify a model based on little or no prior data, and therefore some dependence
on the assumed model and the prior distribution is inevitable. Second, the conduct of such
studies requires substantial attention, potentially a complete reanalysis of the data and re-
evaluation of the dosing scheme at the time of enrollment of each new patient. (34) This
activity requires more statistician and clinician time than many institutions can afford to
allocate. This appears to be the primary reason that these designs have not come into wide





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PROJECTING CLINICAL TRIAL RESULTS TO A TARGET POPULATION
3.1. Introduction
A clinical trial lacks external validity if the sample in which it takes place differs in impor-
tant ways from the target patient population in which one intends to apply its findings.(7,
33, 52) Of particular concern is the estimated treatment effect, which describes the potency
of a new treatment and predicts the consequences of its widespread adoption. A trial whose
estimated treatment effect differs from its value in the target population may misinform
clinical practice, leading to sub-optimal therapy of future patients.
If one possesses data on the distribution of predictors of outcome in the target population,
and one expects treatments to have similar effects in relevant subsets of the trial and target
populations, then it is in principle possible to project treatment effects to this population.(27,
40, 53) We denote this process interpolation, because we assume that all relevant subsets
occur in both the trial sample and the target population.
In the traditional interpolation method of post-stratification, we partition the trial par-
ticipants into strata defined by a set of covariates that exhibit interaction with treatment
effects. We compute treatment effects within these strata, and average the effects weighted
by the fractions of subjects in the population that lie within the relevant strata. The method
is model-independent, and is known to work well when the list of confounders is short.(48)
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Contemporary approaches to interpolation rely on variants of propensity score analysis,
in which one estimates the probability of trial inclusion for each subject in the trial. One can
then use the inverse inclusion probabilities as weights in constructing a corrected population
treatment effect estimate.(10, 49) Stuart et al. applied such a method to data on a school-
based cluster trial that was conducted in Maryland, using a list that contained relevant
demographic data for all eligible schools in that state.(48)
Alternatively, one can estimate the population treatment effect by creating strata based
on the inclusion probabilities, analogous to a stratified propensity score analysis. One then
constructs stratum-specific treatment effect estimates and averages them to obtain an overall
estimate that represents the target population. This approach avoids the problem of exces-
sively variable weights and therefore can be numerically more stable.(38) Matching groups
using trial inclusion probabilities is similar to dividing the subjects into subgroups when the
two methods use the same classification variables.(49, 50)
Inclusion probability methods are rarely applicable in medical trials, because the neces-
sary population data set — a census of trial-eligible patients with all relevant confounders
recorded — seldom exists. Potential exceptions include rare diseases with comprehensive reg-
istries, or diseases that are recorded in national health databases, as some European countries
maintain. More commonly, the best population information would come from health sur-
veys such as the US National Health & Nutrition Examination Survey (NHANES). (8) But
although NHANES collects extensive demographic, behavioral, and health history data, its
disease variables are largely self-reported and therefore potentially imprecise. One may be
able to use NHANES as a reliable basis of population data for trials of common, non-specific
conditions like hypertension and hypercholesterolemia, but it is less useful for conditions
whose diagnosis depends on elaborate or expensive tests or procedures.
In this article we discuss these methods and illustrate their application in pharmaceutical
research. We begin by describing a clinical trial that manifests a need for interpolation.
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3.2. Example: The LRC-CPPT
The Lipids Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a ran-
domized, double-masked, placebo-controlled study of the effect of cholestyramine on long-
term cholesterol reduction and incidence of coronary heart disease.(30) Briefly, the study
randomized over 3,700 men within strata defined by cardiovascular risk. Investigators di-
rected participants to consume six packets a day of the assigned treatment — either active
cholestyramine or a placebo. Follow-up visits took place two weeks after randomization and
at 2-month intervals for an average of 7.4 years. The outcome variable is the difference be-
tween average cholesterol measurements taken after randomization and a weighted average
of baseline measurements.(14)
Several measured covariates in the LRC-CPPT trial have different distributions in other
populations where one might wish to treat for hypercholesterolemia. For example, the pro-
portion of ever-smokers in the study, conducted between 1973 and 1983, was 76%, whereas
in the US population currently it is 45%.(8) If smoking moderates cholestyramine effects, an
estimated treatment effect derived only from trial data may be misleading.
3.3. Methods
3.3.1. Estimating the treatment effect in the trial
Let Yi(Zi) be the potential outcome for subject i when randomized to treatment Zi (1 =
experimental, 0 = control). The causal effect of randomization for subject i is the difference
between its experimental and control potential outcomes: Yi(1)− Yi(0). The causal effect in









where n is the trial sample size and ER refers to the sampling of subjects into the trial.(21)
Because we can observe a subject’s outcome only under the assigned treatment, we denote
the observed outcome Yi = ZiYi(1) + (1−Zi)Yi(0). Under assumptions of random treatment
assignment and no interference between units (the stable unit treatment value assumption),






















Y,1 are the sample variances of Y in the groups randomized to control and ex-
perimental treatment, respectively. Alternatively, one can estimate Υ via a linear regression
model on Y with an intercept, a slope on Z, and normal residuals E:
Y = α + ZΥ + E. (3.2)
This approach gives the same result as estimating the ITT effect of Z on Y in Equation
(3.1), with the difference that the SE is based on a pooled variance estimate.
Another analysis — denoted an analysis of covariance — would estimate the treatment
effect with model-based adjustment for baseline covariates X:
Y = α +Xβ + ZΥ + E. (3.3)
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In a randomized trial, the estimate of Υ from Model (3.3) will differ from that from Model
(3.2) due to variation in the distribution of X, but their expectation is the same. To de-
tect whether there is heterogeneity of the treatment effect — defined here as meaning that
the treatment effect varies across subgroups defined by the covariates — one can create a
regression model that includes the randomization indicator, covariates, and interactions:
Y = α† +Xβ† + ZΥ† + ZXγ† + E. (3.4)
We refer to the estimand here as Υ†, because it is not in general the same parameter as Υ,
which represents a treatment effect averaged over the distribution of covariates in the trial.
We call a covariate that manifests a significant interaction with the randomization variable
a moderator of the treatment effect. Note that the error variances estimated from Models
(3.2), (3.3), and (3.4) differ in expectation, generally decreasing as one adds terms to the
model.
3.3.2. Interpolation with post-stratification
3.3.2.1. Post-stratification with a discrete stratifier
The objective of our analysis is to project a standard clinical trial treatment effect esti-
mate to its likely value in the ultimate target population. For notational convenience, we
recode the moderator X variables into a single stratifier S that takes values sj, j = 1, . . . , J .
In medical trials the stratifiers would typically be some combination of demographic vari-
ables, pre-treatment risk factors such as smoking status, indicators of disease type or severity,
and biomarkers. We assume that we know the distribution of S in the target population.
Let fT (s) and fP(s) represent the probability mass functions of the stratifier in the
trial and target population, respectively. Letting Υˆj be the estimated treatment effect from
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stratum j, then the raw clinical trial estimate Υˆ from Equation (3.1) is approximately




The two estimates are only approximately equal because slight imbalances will arise in the
randomization within strata in finite samples.
To create an estimated treatment effect ΥˆP that reflects the distribution of the stratifier















This is the classical post-stratification estimate and variance.
It is elementary to show that if E[ΥˆT ] 6= E[ΥˆP ], then i) there is a treatment-by-stratum
interaction; i.e., ∃ j 6= k such that E[Υˆj] 6= E[Υˆk] ; and ii) the trial and population weights
differ; i.e., ∃ j : fP(sj) 6= fT (sj). Clearly, if treatment effects do not vary across strata,
then the weighting scheme cannot alter the expectation of the weighted estimate. Moreover,
unless the trial and population stratum proportions differ, again reweighting can have no
effect. Although these conditions are not sufficient, a trial in which both are satisfied presents
a prima facie case for interpolation.
One can implement post-stratification using the ESTIMATE statement in SAS PROC GLM.
For example, if smoking is the sole stratifier, one can estimate the effect among smokers
using “ESTIMATE Z 1 -1 Z*smoke 1 0 -1 0/E;” and the effect among non-smokers using
“ESTIMATE Z 1 -1 Z*smoke 0 1 0 -1/E;”. To post-stratify by smoking, where the pro-
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portion of smokers in the population is, say, 80%, one can use “ESTIMATE Z 1 -1 Z*smoke
0.8 0.2 -0.8 -0.2/E”.
3.3.2.2. Post-stratification with a continuous stratifier
When S is so fine as to be effectively continuous, each stratum may contain only one or
a few observations, and thus estimates can be undefined within strata. Instead, we use a
smoothing approach. For each sj (assuming sorted values), create the moving window set
σj = {max(sj − d,min(S)), . . . ,min(sj + d,max(S))}. (3.7)
and replace Υˆj in (3.5) by the corresponding treatment effects estimated on σj. An alterna-
tive smoother computes stratum treatment effects using the k nearest neighbors. That is,
for each sj, include in σj the k subjects whose S values are closest to it.
When multiple subjects share the same S value, the resulting subset can have more
than k subjects. In LRC-CPPT we implemented this method, interpolating on age with
k ≈ 5N/J . To avoid over-smoothing on the boundaries, we set k ≈ 3N/J when j = 1 or
j = J ; in our applications, this gave similar results to a window size of d = 2. Estimates on
the boundaries are typically smoother with the nearest-neighbors approach. With multiple
continuous stratifiers, one can define a multivariate measure for distance, then extract the k
nearest neighbors.
For continuous S, we generally do not have independence across strata, and therefore we
cannot use Equation (3.6) to compute standard errors. Instead, we compute a bootstrap SE
under strategy (3.7), resampling (Zi, Yi) within strata.
When there are multiple stratifiers, all of them continuous, one can select discrete pseudo-
strata for each point based on nearest neighbors according to some multivariate distance
measure. When there are both continuous and discrete stratifiers, it is preferable to first
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select pseudo-strata by continuous predictors, and then stratify within those based on discrete
stratifiers. This avoids the problem of empty strata, as occurs in LRC-CPPT, where there
are, for example, no non-smokers aged 34.
3.3.3. Interpolation with inverse inclusion probability weighting
Stuart et al. (48) proposed computing for each subject the probability of being selected
into the trial, then using the inverse of the inclusion probability, W IIPWi , as a weight in
estimating causal effects. The estimate of the effect of Z on Y using inverse inclusion














When the stratification is categorical and includes all covariates, the trial inclusion score for
subject i in stratum j is pij =
nj
Nj








where nj and Nj represent the total numbers of subjects in stratum j in the trial and target
populations, respectively. In the Appendix, we show that the individual inverse inclusion
probability weights approximate the weights implied in the post-stratification scheme using
the same set of stratifiers. The two approaches are equivalent when randomization fractions
are equal in all strata, as would occur in large samples.
3.3.4. Interpolation with inclusion probability stratification
One can also use the trial inclusion probabilities in an alternative post-stratification
approach, we denote this as inclusion probability stratification (IPS). Specifically, one re-
29
defines S by creating pseudo-strata that group together the trial observations based on
their trial inclusion scores. One then computes treatment effects within the strata and use
Equation (3.5) to reweight them based on the distribution of S in the target population. As
with propensity score analysis, dividing into five strata of equal size appears to be sufficient
to reduce the bias to negligible levels.(42) Moreover, stratification with a modest value of J
leads to an estimate that is more numerically stable than ΥˆP,IIPW.
3.3.5. Computing standard errors with inclusion probabilities
3.3.5.1. The standard error of the IIPW estimate
One can compute the IIPW estimate either directly using Equation (3.8) or through a
weighted regression. Setting U = [1 Z] and defining W to be a square matrix with the
weights Wi on the diagonal, one obtains
δˆP,IIPW = (UTWU)−1UTWY (3.9)
where δˆP,IIPW = [αˆP,IIPW, ΥˆP,IIPW]. The estimated variance is
V(δˆP,IIPW) = (UTWU)−1UTWσˆ2IWU(UTWU), (3.10)
where σˆ2 is the sample variance of the residuals, divided by W . Although ΥˆP,IIPW is consis-
tent for the population treatment effect ΥP , its nominal residual variance may greatly exceed
that created from classical post-stratification. This is because the latter is based implicitly
on a model that includes all relevant predictors of outcome (as in Model (3.4)), whereas the
former includes only Z (as in Model (3.2)). To correctly estimate the residual variance and
treatment effect variance, one should substitute the estimated residual variance from Model
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(3.4) into Equation (3.10).
3.3.5.2. The standard error of the IPS estimate
Similarly, the IPS approach gives an inflated SE if there is substantial heterogeneity in










with nj1 and nj0 equal to the number of patients in stratum j in the experimental and control
arms, respectively. We apply Equation (3.6) with fP(sj) to get the correct SE. Again, one
should substitute the residual standard deviation from Model (3.4) into Equation (3.11).
By contrast, if in the conventional post-stratified analysis we assume a common value of
the within-stratum variance σ2, then this equals the variance under Model (3.4), and there
is no need to further adjust the standard errors.
3.4. Simulation study
We conducted a one-replicate simulation study to illustrate the potential bias from omit-
ting important covariates in projecting a population treatment effect estimate. We created a
synthetic population consisting of six copies of the LRC-CPPT trial dataset (randomization
and covariates only). Next we generated an outcome for which education, smoking, and age
group exhibit no, moderate, and strong interaction, respectively, with treatment assignment:
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Y = −2 + 20× Z − 2× smoke + 3× agegroup
+0.5× education− 0.25× Z × smoke
+12× Z × agegroup + E,
where E is a vector of independent N(0, 32) deviates. The variable agegroup is coded as
equally spaced groups representing three age levels: < 44, 44–50, and ≥ 51. We also divided
education into three groups — less than high school, high school graduate, and some college
and above. Because there are substantial interactions, the population treatment effect,
representing an average of treatment effects across strata, need not equal 20, the coefficient
of the randomization indicator Z in the mean model. Finally, we selected a sample of subjects
to constitute the trial population via the logistic model
logit(p) = −2.5− 0.5× smoke + 0.28× age group + 0.6× education;
here p is the probability of being selected into the trial. From the resulting synthetic popu-
lation of 22,704 subjects we sampled 3,786 to become the synthetic trial dataset.
Table 3.1 displays estimated treatment effects from the synthetic population, the syn-
thetic trial, IIPW using the true and estimated trial inclusion scores, IPS on inclusion scores,
and post-stratification using all possible combinations of the three stratifiers. Our ground
truth, from the synthetic target population, is ΥP = 32.11; compare this to ΥˆT = 33.58
(SE=0.30) from the synthetic trial. Estimates from IIPW matched the target population
values well, regardless of whether we used true or (correctly) estimated probabilities. The
treatment effect from the stratified inclusion score analysis gave ΥˆP = 31.42 (SE =0.25), and
therefore was off target by almost 3 standard errors; moreover its estimated standard error
was twice that from a weighted analysis. Using the corrected residual variance estimate from
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Model (3.4) — including treatment, strata, and interactions — we obtained an SE of 0.11.
The correlation between the post-stratification and the true trial inclusion score weights
for our simulated data was 0.95; the relationship was not perfectly linear due to a slight lack
of balance. Estimates by post-stratification were close to the truth and precise provided that
age, the variable with the strongest interaction with treatment, appeared as a stratifier.
Table 3.1. Estimated treatment effect (SE) on drop in cholesterol (mg/dL) from simulated
LRC-CPPT data. Selection into the trial was based on age group, smoking status, and
education.
Method ΥˆT
Synthetic trial (N = 3,786) 33.58 (0.30)
ΥP
Synthetic population (N = 22,704) 32.11
Trial inclusion score analysis ΥˆP
IIPW with true score 32.22 (0.30)
IIPW with true score weighting, corrected variance 32.22 (0.10)
IIPW with estimated score 32.15 (0.30)
IIPW with estimated score, corrected variance 32.15 (0.10)




Age group 32.23 (0.11)
Education+smoking 33.92 (0.31)
Education+age group 32.27 (0.11)
Smoking+age group 32.20 (0.10)
Education+smoking+age group 32.23 (0.11)
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3.5. Analysis of the LRC-CPPT Data
A stepwise variable selection found age and smoking status to have significant interactions
with treatment assignment (Table 3.2). Estimated treatment effects by smoking status and
by race for LRC-CPPT appear in Table 3.3. The proportion of smokers in LRC-CPPT
was 76%, compared to current estimates from NHANES that 45% of Americans are ever-
smokers.(8) Applying Equation (3.5) with the distribution of smokers from NHANES we
obtain ΥˆP = 28.02 (SE=0.90), compared to ΥˆT = 26.91 (SE=0.80) in the trial. Although
the treatment effect appears to differ by race (Table 3.3), only 3.4% of trial subjects identified
as black, and the race-treatment interaction was not significant (P = 0.51). Therefore, we
excluded race as a stratifier in further analyses.
Table 3.2. Estimated coefficients (SE) from stepwise selection.
Intercept Treatment Age Smoke Treatment × Age Treatment × Smoke
−9.30 (4.23) 7.11 (5.95) 0.35 (0.08) 0.24 (1.31) 0.51 (0.12) −5.52 (1.84)
Table 3.3. Intention-to-treat estimates (SE) by stratum from LRC-CPPT; outcome is the
drop in cholesterol (mg/dL).
Smoking Race
Non-smoker Smoker Non-black Black
(N = 904) (N = 2880) (N = 3655) (N = 129)
Υˆ 30.96 (1.66) 25.62 (0.91) 26.81 (0.81) 29.70 (4.63)
The age-by-randomization interaction was significant at P < 0.0001. As age is effectively
continuous, we created interpolated estimates using moving windows of size d = 2 from ages
34 to 60. Figure 3.1 shows that the treatment effect increases dramatically with increasing
age.
To obtain a population that better reflects disease status, we abstracted information from
NHANES, which collects serum cholesterol values and therefore can identify subjects who
34
Figure 3.1. Estimates of average cholesterol drop by age.




























would be eligible for treatment with a cholesterol-lowering drug. We combined data from
1999 to 2016, restricting attention to males aged 34–60.(8) Retaining only those who meet
the LRC-CPPT hypercholesterolemia criteria, we ended up with 120 subjects. Expanding to
the contemporary definition (total cholesterol ≥ 200 mg/dL; LDL cholesterol ≥ 100 mg/dL;
triglycerides ≤ 300 mg/dL) yielded 2,118 subjects. From these data, we interpolated causal
estimates by smoking and age, computing SE by the bootstrap. The interpolation led to
a two mg/dL increase in the estimated treatment effect, representing approximately 2.5
standard errors; see Table 3.4.
We computed trial inclusion probabilities using hypercholesterolemic male NHANES par-
ticipants to represent the target population. Eligible individuals were weighted by their
NHANES sampling weights, which reflect their representation in the US population. Trial
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subjects took weights of 1, as they represent only themselves. We estimated the inclusion
probability with a logistic model including age and smoking status. We then conducted an
analysis by inverse weighting of trial subjects’ estimated inclusion probabilities, as well as
an analysis stratified by trial inclusion probabilities. The results were similar to the inter-
polated estimates using measured stratifiers (Table 3.4) but 1 SE smaller than those from
classical post-stratification. The SE for the interpolated estimates in the stratified analysis
was similar to that using the pooled variance estimate from Model (3.4). The disparity
was not as great as in the simulation study, because the interaction between age group and
treatment was not as strong in the LRC-CPPT dataset.
Table 3.4. Interpolated treatment effect (SE) on drop in cholesterol (mg/dL) based on the








We have described and applied methods for projecting a treatment effect estimate to
a population that differs from the one in which the treatment was evaluated. Common
assumptions of the methods are that i) subjects in the trial are similar to those in the target
population, other than on a set of measured covariates, and ii) information is available on
the distribution of these covariates in the population.
The drive to create personalized treatment strategies has heightened interest in the ef-
ficient estimation of treatment effects within subgroups. Nevertheless there is a continuing
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need to estimate average treatment effects in the general population of subjects with a given
disease. For example, economic evaluation, such as cost-effectiveness analysis, relies on esti-
mated effects on survival and cost for the population. This is true whether the “treatment”
is a single drug administered to all comers or a personalized strategy that depends on phar-
macogenetic markers.
In our simulation, post-stratification on a covariate that displayed a strong interaction
with treatment gave estimates that were close to the truth and to estimates from an inverse-
probability-weighted approach that correctly used all relevant confounders. This suggests
that interpolation by post-stratification can offer a reliable sensitivity analysis in the common
situation where subject-level population data are unavailable. One can control the number
of strata in the analysis by limiting attention to covariates that have strong interactions with
treatment, as assessed from the trial data. We observed that an approach that segregates
subjects into strata based on trial inclusion scores was less successful.
When all stratifiers are discrete, post-stratification weights are comparable to those based
on inverse trial inclusion probabilities, and therefore the two methods give similar estimates.
With continuous stratifiers, methods based on trial inclusion scores are potentially more
accurate, because the scores can better reflect study inclusion probabilities. Stratum sizes
may be small, however, and validity of estimates is hostage to correct model specification.
Moreover, to obtain correct SEs with the inclusion probability approaches, one must conduct
the extra step of estimating the variance with a model for Y that includes the treatment, the
stratifiers, and treatment-stratifier interactions. When individual-level data are not available
for the target population, it is not possible to directly compute trial inclusion probabilities.
One can circumvent this problem by generating a pseudo-population using the estimated
distribution of stratifiers. Post-stratification works well without the need for this extra step;
moreover, it automatically avoids the problem of inflated SEs.
We followed the practice of the authors of the original example paper by taking the
response variable to be the difference between follow-up and baseline values of cholesterol.(14)
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This may be inefficient compared to estimation by analysis of covariance; (15, 45) in practice
it is preferable to work with baseline-adjusted treatment effects within strata.
It is often said that trial participation has a positive effect, even for patients who are
assigned to control therapy. This is because participants typically receive state-of-the-art
treatment with frequent evaluation, and may enjoy other benefits such as reduced health care
costs.(52) Patients who are likely to adhere well to treatment may also be over-represented in
clinical trials. Nevertheless there is substantial evidence that treatment effects in randomized
and observational studies are similar,(37, 40) supporting the use of interpolation as described
here.
When the target population includes strata that are absent from the trial population,
interpolation is impossible. LRC-CPPT, for example, excluded females and persons outside
the age range 34–60. We refer to the projection of treatment effects to a population in which
there are additional strata as extrapolation, because it involves averaging estimated stratum
effects that lie outside the range of the trial data. For variables like age, one can extrapolate
effect estimates using regression models, subject to the usual caveat about projecting beyond
the range of the data. For variables like sex, where an entire stratum is absent by design, one
can conduct sensitivity analyses, perhaps involving estimated treatment effects from other
trials if any are available.
A related concern is that both the post-stratification and inverse-probability weighting
assume that the clinical trial and target populations differ only with respect to the distribu-
tion of measured stratification variables. In some cases, the decision to participate in a trial
may represent the outcome of a nonignorable selection mechanism, which one can think of
as the target and trial populations differing also on unmeasured confounders. An important
future direction is to address this concern via sensitivity analysis. (35)
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CHAPTER 4
PROJECTING INSTRUMENTAL VARIABLE RESULTS TO A TARGET
POPULATION
4.1. Introduction
A randomized clinical trial assesses the efficacy of a treatment among patients who par-
ticipate in the trial, but its results may not be directly applicable to the target population
for which the treatment is intended. Such concerns typically arise when the trial sample is
not representative of the target population.(7, 33, 52) If the treatment effect differs by sub-
groups, and the subgroups are represented differently in the trial, then the treatment effect
from the trial will differ from that in the target population. Such a trial may misinform
clinical practice, leading to sub-optimal treatment of future patients.
If one can i) identify all covariates that have an interaction with treatment, ii) accurately
measure the joint distribution of those covariates in the population, and iii) safely assume
that the treatment effects in the target population match those in the trial, then it is in
principle possible to project treatment effects from the trial to the target population. We
denote this process as interpolation.
A classic method for interpolation is post-stratification, in which one reweights stratum
treatment effects from the trial to the target population.(29) This approach requires only
that one know the distribution of key covariates in the population. If individual-level data
are available in the target population, it is possible to obtain estimated probabilities of
trial inclusion for each subject in the trial. One can then obtain projections by using these
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probabilities either in a weighting scheme (10, 48) or as the basis for post-stratification,
applying a method reminiscent of propensity score analysis.(38)
The intention-to-treat (ITT) approach is the standard paradigm for clinical trial data
analysis. The essence of this approach is to include all randomized subjects and to analyze
a measured “hard” endpoint with subjects grouped according to randomization arm, even
if some did not receive the assigned treatment. The estimand is the effect of the treatment
as assigned, which is arguably more relevant to practice than its effect in a hypothetical
situation of universal perfect adherence. We have discussed interpolation of ITT estimates
previously.(29)
Alternatively, one may wish to estimate a treatment effect in compliers, or the notional
population of subjects who would adhere to assigned treatment. A problem with this ap-
proach is that we cannot generally identify compliers. For example, some subjects who
were assigned and received control therapy would also have taken control therapy if assigned
the experimental intervention, in which case they are never-takers rather than compliers.
Such considerations have led to the development of analysis methods grounded in the Ru-
bin causal model.(21, 43, 44) This framework enables estimation of the treatment effect
among compliers, the complier average causal effect (CACE), by means of instrumental
variables analysis.(3, 47) Other methods for examining treatment effects in light of compli-
ance use ad hoc approaches (14) or more elaborate applications of the concept of principal
stratification.(5, 16, 17, 26)
In this chapter we present a post-stratification approach that interpolates causal esti-
mates from a clinical trial to reflect the distributions of predictive covariates in a larger,
clinically relevant population using instrumental variable approach on CACE.(3) We com-
pare post-stratification with two other approaches using trial inclusion probabilities. We
assume that trial participants are similar — in terms of outcomes and compliance behavior




The Lipids Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a
randomized, double-masked, placebo-controlled study of the effect of cholestyramine on long-
term cholesterol reduction and incidence of coronary heart disease.(30) Over 3,700 men were
randomized in strata grouped by cardiovascular risks. Participants took six packets of either
cholestyramine or placebo each day (24 grams per day). Follow-up visits occurred two weeks
after randomization and every two months, for an average of 7.4 years. Patients reported
the number of assigned packets consumed during each follow-up visits. We take as outcome
variable the difference between average cholesterol measurements taken after randomization
and a weighted average of baseline measurements.(14)
Because cholestyramine was unpleasant to use, nonadherence was common. For the
purposes of this analysis, we designate a complier as a patient who took at least 80% of
his assigned packets, in which case roughly half of subjects in the cholestyramine arm are
non-compliers. We seek to estimate treatment effects considering compliance.
LRC-CPPT participants differed from the contemporary population of US males both
with respect to smoking habits and the distribution of age. We will use data from the trial
and from the US National Health & Nutrition Examination Survey (NHANES) to examine
the hypothesis that these differences could affect estimates of causal treatment effects.
4.2.2. New York School Choice Experiment
In 1997, the School Choice Scholarships Foundation conducted a study of the effect of
private school vouchers on the educational achievement of children from low-income fami-
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lies in New York City.(5, 18) The Foundation chose recipients by lottery from a cohort of
applicant families. The control arm was a set of non-recipients who were pair-matched to
the recipients via a propensity-score model. Thus treatment was assigned at random, albeit
not in the conventional way. Subjects sat for the Iowa Test of Basic Skills, which evaluates
ability in reading and math, both before randomization and after the following school year.
We take as outcome the grade-normed national centile rankings on reading and math.
To avoid various complications, we focus on 715 subjects from single-child families with
children in grades 1–4 during the application period and who had complete demographic,
baseline, and follow-up data. Treatment adherence was imperfect, as some voucher recipients
declined to attend private schools, and some non-recipients attended private schools at their
own expense.
The cohort that we analyze was roughly equally divided between black and non-black
students, whereas the population of NYC at the time was 30% black, and the US population
was 14% black. As treatment effects plausibly differ between races, causal effects of the in-
tervention, were it to be applied across all of NYC or the entire US, could differ substantially
from those observed in the study.
4.3. Causal estimands and their estimates
4.3.1. The ITT estimand
Henceforth, we adopt the notation of the Rubin causal model.(3) Let Yi(Zi, Di) be the
potential outcome for subject i, i = 1, . . . , n, when randomized to treatment Zi and taking
treatment Di = Di(Zi) (1 = experimental, 0 = control). The causal effect of randomization
for subject i is the difference in outcomes that would have occurred under treatment and
control: Yi(1, Di(1)) − Yi(0, Di(0)). Under some assumptions — the stable unit treatment
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value assumption (no interference between units), and random treatment assignment — the
causal effect in the trial sample is
∑n
i=1 [Yi(1, Di(1))− Yi(0, Di(0))]
n
,
and the causal effect in the population is
ΥITT = ER
[∑n




where n is the sample size in the trial and ER refers to the sampling of subjects into the trial.
We typically think of the expectation operator ER as representing simple random sampling
from a notional population of subjects who have the disease in question and are able and
willing to participate in a trial.(21) In many medical applications, however, it is clear that
the notional population is not the same as the target population of subjects who have the
disease and would be eligible to take the experimental treatment if it were available.
We can observe a subject’s outcome only under the treatment to which he is randomized.
For example, if Zi = 1, only Yi(1, Di(1)) is available, and Yi(0, Di(0)) is an unobserved
potential outcome. For convenience, we denote the observed outcome Yi = ZiYi(1, Di(1)) +










also known as the intention-to-treat estimate of the treatment effect. Therefore we can also









where s2Y,0 and s
2
Y,1 are the sample variances of Y in the groups randomized to control and
experimental treatment, respectively.
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4.3.2. The effect of randomization on compliance
The intention-to-treat estimand ΥITT measures the causal effect of randomization on
response, without consideration of compliance. To measure the treatment effect among
compliers, it is necessary to consider the effect of treatment assignment on compliance. We
denote this estimand as











to be the fraction of patients in the treatment group





to be the fraction of patients
taking experimental treatment in the control group. The causal effect of randomization on
treatment received is then δITT = pi1 − pi0. Assuming no defiers (i.e., Di(1) ≥ Di(0)), this
quantity measures the proportion of compliers.
Letting pˆi1 and pˆi0 be the estimates of pi1 and pi0, respectively, from trial data, define




















D,1 are the sample variances of D in the control and experimental arms, respec-
tively. As Di is binary, s
2
D,0 = pˆi0(1− pˆi0), and s2D,1 = pˆi1(1− pˆi1). When the control arm has
no access to the experimental treatment (as in the LRC-CPPT example), Di(0) = 0 ∀i, and




4.3.3. The complier average causal effect
To measure the treatment effect among the latent subgroup of compliers, or subjects for
whom Di(Zi) = Zi, we define the complier average causal effect (CACE)
ΥCACE = ER [Yi(1)− Yi(0)|Di(1)−Di(0) = 1] .
Under two further assumptions — the exclusion restriction (Y depends on Z only through
D), and a nonzero average causal effect on compliance (3, 21, 47) — CACE simplifies to
ΥCACE =



















where V(·) and C(·, ·) are sample variance and covariance operators.(21)
4.4. Interpolation of estimands and estimates
We here discuss methods for projecting causal estimates from a clinical trial population
to a target population that differs from it with respect to the distribution of important co-
variates.
46
4.4.1. Interpolation with post-stratification
Post-stratification is a traditional projection method for that reweights treatment effects
within subsets of the trial population by weights that reflect the proportion of the subset
in the target population. Assume that we have recoded all relevant covariates X into a
single stratification variable S that takes values sj, j = 1, . . . , J . As it is necessary to have
enough data to estimate the treatment effect separately within each stratum, the presence
of continuous or finely measured covariates can complicate analysis. We circumvent the
problem of small strata by grouping together similar strata so that all have a workable
minimum size.
4.4.1.1. Post-stratification of the ITT estimand
Let fT (s), fP(s) represent the distribution of the stratification factor in the trial and
target populations, respectively. The ITT estimand in the trial population is ΥTITT =∑
j f
T (sj)ΥITT,j, where ΥITT,j is the estimand in stratum sj. Similarly, the ITT estimand




Letting ΥˆITT,j be the ITT estimate from stratum j in the sample, then the clinical trial
ITT estimate from Equation (4.1) is approximately




The two estimates will may differ slightly due to small imbalances of randomization within






In order for there to be a difference in estimands (E[ΥˆTITT] 6= E[ΥˆPITT]), there must be an
interaction between treatment and stratum, and the trial and target distributions of S must
differ.(29)
4.4.1.2. Post-stratification estimate of CACE












. Letting δˆITT,j be the estimated effect on compliance in stratum





Under the assumptions of IV estimation, for the target population we get ΥPITT = δ
P
ITT×










To estimate CACE in the target population, one must therefore interpolate the numerator





4.4.1.3. Standard errors of the interpolated estimates






















The delta-method standard error in Equation (4.2) can be unstable. A practical alternative,
which we have implemented in our examples, is to compute the SE by the bootstrap, re-
sampling triples (Zi, Di, Yi) within strata. To make the results reproducible, we recommend
resampling at least 5,000 times.
4.4.2. Interpolation with inverse inclusion probability weighting
Stuart et al. (48) proposed an interpolation method that mimics propensity score analy-
sis. First one computes, for each subject in the trial, the probability of being selected into the
trial; we denote the inverse of this probability as W IIPWi , which we then use aa an analysis















We have shown that this estimate is approximately equal to the post-stratified estimate when
using the same set of discrete stratifiers. The two approaches give identical results when we
have equal randomization in all strata.(29)




















We will discuss the SE of interpolated estimates from IIPW in Section 4.4.4.
4.4.3. Interpolation with inclusion probability stratification
One can also use the trial inclusion probabilities to conduct a stratified analysis.(38) With
this approach, one creates strata based on the estimated inclusion scores, then conducts a
post-stratified analysis using these newly derived strata. An advantage of this method is
that, like propensity score analysis for observational data, it appears to work well with as
few as five created strata.(42) It also avoids issues the potential instability of the weighted
analysis, and the need to artificially combine strata to avoid small numbers.
Formally, we define an artificial stratification variable SIPS that takes values sIPSk , k =
1, . . . K, based on quantiles of the inclusion probabilities. Then we can compute an estimated
ITT effect ΥˆITT,k in each s
IPS
k from the trial data, and apply Equations (4.3) based on the





If one uses the quantiles of inclusion probabilities as observed in the trial, the number of
observations is balanced in each stratum. Alternatively, if one defines quantiles from the
target populations, we have fP(sIPSk ) = 1/K ∀ k.
One can readily extend this approach to estimate the CACE: First interpolate within-
stratum estimates of compliance δˆITT,k to get δˆ
P,IPS







We will discuss SE estimation in Section 4.4.4.
4.4.4. Implementation
4.4.4.1. Selection of stratifiers
The first step is to identify a relevant set of covariates. As a rule, one should include in
the stratification any covariate that is associated with heterogeneity of randomization effects
on either the outcome or treatment received.
To check for heterogeneity of treatment effect by covariates, one can use a model including
randomization, covariates (X), and interactions between randomization and covariates on
response: (29)
Y = α† +Xβ† + ZΥ† + ZXγ† + E, (4.9)
where E is Normally distributed with variance σ2y. Note that the treatment effect Υ
† is not
the same as ΥITT, which is the treatment effect averaged over the covariate distribution.
When control subjects have access to the experimental treatment (as in the New York
School Choice Study), we can similarly conduct a regression ofD onX, Z, and the interaction
of X and Z to identify covariates for which treatment effects are heterogeneous:






d + Ed. (4.10)
Although one would usually use a generalized linear model with a logit link function in this
context, because the treatment effects on adherence are to be measured on the probability
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scale, it is preferable to use an identity link for this model. (1) Moreover, we use the estimated
residual variance from this model, call it σˆ2d, in subsequent SE calculations.
When subjects in the control group have no access to the experimental treatment (as
in LRC-CPPT), any covariate that is associated with D in the experimental arm has an a
fortiori interaction with randomization. Therefore in this case we evaluate covariate effects
from a reduced model that excludes interactions, using data on the experimental arm only.
4.4.4.2. Standard errors for the IIPW estimates
We have observed that one can compute the IIPW estimate of the effect of randomiza-
tion on Y via a weighted regression of Y on Z using the inverse inclusion probabilities as
the weights. Unfortunately, the default SE from this approach may be many overestimate
variability, as it does not account for heterogeneity of effects across values of X. Instead, one





propriately chosen Ai values. An efficient SE is then SE(Υˆ
P,IIPW




i , where σˆ
2
y is
the estimated variance from Equation (4.9). This renders the SE from this approach roughly
equal to the SE from post-stratification with an equivalent set of included covariates. To
compute the SE for δˆP,IIPWITT one uses a similar approach, but substituting σˆd from the linear
regression of D in the model for heterogeneity.(1) Because the delta method variance for the
ratio of treatment effects can be inaccurate and unstable, in particular if the denominator
effect is modest, it is preferable to compute SEs by the bootstrap.
4.4.4.3. Standard errors for the inverse probability stratification estimates
To compute the SE of ΥˆP,IPSITT , one simply computes the SE using the post-stratification
approach, but substituting σˆy from Model (4.9) as the standard deviation term.(29) Similarly,
to estimate the SE of δˆP,IPSITT one substitutes σˆd from Model (4.10) as the standard deviation
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term. In computing the SE of ΥˆP,IPSCACE it is generally preferable to use the bootstrap, for
reasons described above.
4.5. Simulation study
We conducted a simulation study to i) compare interpolated causal estimates from post-
stratification and two approaches using inclusion probabilities; and ii) demonstrate how
selection of covariates for post-stratification affects the results. We created a synthetic target
population by making six copies of the LRC-CPPT trial dataset (randomization, compliance,
and covariates only).
To generate a variable for actual treatment received, we first created a continuous variable
C so that compliance depend on randomization, smoking status, and age:
E(C) = 1.8× Z − 0.05× smoke + 0.05× age.
In the trial, we assumed patients assigned to take placebo did not have access to the treat-
ment, so we did not include interaction terms between randomization and covariates on
compliance. We added independent N(0, 0.362) deviates to C and set D = 1 if C > 4.1, so
that all the patients in the control group have D = 0, and the fraction of compliers was close
to 52% in the synthetic target population, as observed in the actual clinical trial dataset.
Next we generated an outcome for which education, smoking, and age exhibit no, mod-
erate, and strong interaction, respectively, with actual treatment received:
Y = −12.2 + 11×D − 2× smoke + 0.3× age + 0.5× education
−0.2× Z × smoke + 0.5× Z × age + E,
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where E represented independent N(0, 32) deviates. We divided education into three groups
— less than high school, high school graduate, and some college and above. We randomly
selected participants for the synthetic trial population with the logistic model
logit(p) = −4.59− 0.5× smoke + 0.05× age + 0.6× education;
where p is the trial inclusion probability. From the resulting synthetic population of 22,704
subjects we sampled 3,792 to become the synthetic trial dataset. We used continuous age for
trial inclusion score analysis, but we divided age into three categories for post-stratification:
< 44, 44–50, and ≥ 51.
Table 4.1 shows the estimated causal effects from the synthetic trial, the synthetic target
population, inverse inclusion probability weighting with true and estimated trial inclusion
probabilities, inclusion probability stratification, and post-stratification with all possible
combinations of education, smoking and age group. The ground truth in the synthetic
population is δˆPITT = 0.52, Υˆ
P
ITT = 29.02, and Υˆ
P
CACE = 56.11. These estimates differed from
the results using the synthetic trial data directly. δˆPITT from all approaches using inclusion
probabilities were close to the ground truth. Interpolated estimates using both the true trial
inclusion scores and estimated trial inclusion scores were within 1 SE of the ground truth.
Post-stratification including age group, the covariate with the strongest interaction with
treatment, returned causal estimates that were closest to the ground truth. Yet even these
estimates were off by 2 to 3 SE. Presumably this is a consequence of having to arbitrarily
group the age variable to render it categorical, as the inclusion probability methods did not
exhibit this bias. Besides, the simulated treatment effects show a strong interaction with




We conducted stepwise variable selection in two models: A regression of cholesterol
drop (Y ) on randomization, covariates, and their interaction in the entire data set; and
a regression of treatment received (D) on randomization and covariates in the subgroup
randomized to cholestyramine (Z = 1). Both analyses identified age and smoking status
as important covariates; therefore we use these variables in all subsequent interpolations.
We also included race, whose interaction with treatment for Y is large but not statistically
significant. In all analyses, we defined compliance to mean taking at least 80% of prescribed
packets, leading to 52% compliance in the cholestyramine arm.
Estimated causal effects by smoking status appear in Table 4.2. The proportion of
smokers in LRC-CPPT was 76%, whereas NHANES estimated that 45% of American males
with hypercholesterolemia are ever-smokers.(8) Applying Equations (4.3), (4.4), and (4.5)
with the distribution of smokers from NHANES we get δˆPITT = 0.53 (SE=0.01), Υˆ
P
ITT = 28.02
(0.90), ΥˆPCACE = 52.55 (1.42), compared to δˆ
T
ITT = 0.52 (0.01), Υˆ
T
ITT = 26.91 (0.80), Υˆ
T
CACE =
51.53 (1.47) in the trial.
We took as our target population males aged 34–60 in NHANES who met current stan-
dards for hypercholesterolemia (total cholesterol ≥ 200 mg/dL; LDL cholesterol ≥ 100
mg/dL; triglycerides ≤ 300 mg/dL). This led to a population of 2,118 subjects. To compute
trial inclusion probabilities, we weighted the subjects in the target population with their
NHANES sampling weights, which reflect representation of these men in the US population.
We assigned LRC-CPPT participants each a weight of 1, as they represent only themselves.
We then estimated a weighted logistic model with age and smoking status, taking T = 1 as
the outcome for trial participation for the LRC-CPPT members and T = 0 as the outcome
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for the NHANES men. The inclusion probabilities were the predicted probabilities of T = 1
for the trial participants.
For the post-stratification, we grouped subjects by age quantiles so that the number
of patients in each category would be similar. We conducted analyses with 2, 5, and 10
subgroups on age to see the effect of the number of subgroups on interpolated estimates.
The total numbers of strata, after combination with smoking status, are therefore J = 4,
10, and 20, respectively. Table 4.3 displays projected estimates of treatment effects, post-
stratified by age group and smoking status. The number of strata had little effect on the
estimates for δˆPITT and Υˆ
P
ITT, but the SE for Υˆ
P
CACE increased with J .
4.6.2. NY School Choice Experiment
A stepwise variable selection for reading score identified no variable with significant in-
teraction with randomization, whereas both race and sex had significant interactions with
randomization for math score. A stepwise variable selection on compliance identified race as
having a significant interaction with treatment. Therefore in subsequent analyses we project
based on race and sex. In analysis limited to two binary covariates, the three interpolation
methods will give identical results, so we henceforth present only post-stratification esti-
mates. We base our interpolations on 2000 US Census data for New York City and the
entire United States.(11, 36)
Table 4.4 shows that males have higher improvement on reading, whereas females and
blacks have higher improvement in math. The proportion of blacks in the study (49.0%) far
exceeds that in the New York City population, which was 29.9% in the 2000 census.(36)
Interpolating to the New York race distribution, the resulting ΥˆPCACE is 3.88 (SE=2.54)
for reading and 2.95 (SE=2.83) for math (Table 4.5). Because the causal estimates differ by
race, the interpolated estimate for math deviates from the trial estimate. Nevertheless the
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difference is within 1 SE.
When interpolating math score for race and sex simultaneously, the overall CACE effect
for non-blacks is close to 0, as the strong positive effect for females and strong negative
effect for males cancel out. The 2000 census in NYC showed that for children aged 6–9
in New York City, 50.7% of non-Hispanic blacks were males, and 51.1% of non-blacks were
males.(36) Using these proportions, the values of ΥˆPCACE are 4.07 (SE=2.49) for reading and
2.35 (SE=2.84) for math. The math estimates differ from the overall estimates using the
trial data, but the difference is less for reading scores. As we identified strong interactions
between randomization and race and sex for math scores, the interpolated math scores show
further deviation from the trial estimates when we post-stratify by both race and sex. When
projected to the entire US population based on the 2000 Census, the causal estimates for
math further deviated from the trial, suggesting that applying the treatment across the
country would lead to modest improvements in performance. Gains for reading would be
sustained, however.
4.7. Discussion
We have described projection of causal estimates from a randomized trial to a target
population using post-stratification, inverse inclusion probability weighting, and inclusion
probability stratification. All the methods require that subjects in the trial are similar
to those in the target population, other than on a set of measured covariates, and that
information is available on these covariates in the population. Furthermore, we assume that
compliance behavior for patients in the trial is similar to those in the target population under
the same subgroup, so that the estimated fraction of compliers in the trial can directly apply
to the target population in the same subgroup.
Before interpolation, one should use the trial data to identify covariates that display a
strong interaction with randomization on either the response or compliance. One can also
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include variables that are likely to evince heterogeneity but may not demonstrate statistical
significance due to sample size limitations. In our simulation study, the estimates using
methods involving inclusion scores were close to the ground truth. Post-stratification results
was less effective, presumably due to its reliance on categorical variables only. Although post-
stratification is less flexible, we can use it to conduct a sensitivity analysis with the joint
distribution of confounders in the target population when subject-level population data are
unavailable.
We have shown that the weights implied in post-stratification is similar to the weights
from inverse of trial inclusion scores using the same set of discrete stratifiers. Therefore, if
all variables are discrete, the three methods will give similar answers.
If subject-level data are not available in the target population, one can create a pseudo-
data set consisting of individuals weighted by their proportions in the population and use
this as the basis of a model for computing trial inclusion probabilities. Again, if all predictors
are categorical, this analysis should closely resemble the post-stratification analysis.
In both data examples, we defined the response variable as the difference between follow-
up and baseline measurements.(5, 14) This is less efficient compared with ANCOVA including
baseline measure, which is more preferable.(15, 45)
Control-group patients in a clinical trial may still observe a positive effect due to benefits
of trial participation such as reduced health care cost and frequent evaluations.(52) Never-
theless, there is evidence showing that treatment effects from randomized experiments are
similar to observational studies, (37, 40) which justifies the use of projection methods.
An important general issue is that failure to adjust for unmeasured confounders — vari-
ables that are both associated with participation and have interactions with treatment —
can lead to biased projections. In the New York School Choice Experiment example, poten-
tial confounders include variables such as school transportation, the availability and quality
of after-school programs, etc., that are likely to differ across the country and affect test out-
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comes. These variables are not available in the dataset or the Census. An important future
direction is to address this concern via sensitivity analysis.(35)
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Table 4.1. Interpolated causal estimates (SE) from simulated data based on LRC-CPPT;
outcome is actual treatment received for δˆITT, and drop in cholesterol (mg/dL) for ΥˆITT and
ΥˆCACE. Selection into the trial is based on age, smoking status, and education. Compliance












Synthetic population (N = 22,704) 0.52 29.02 56.11





IIPW with true score 0.52 (0.01) 29.03 (0.25) 55.67 (1.20)
IIPW with true score, corrected variance 0.52 (0.01) 29.03 (0.20) 55.67 (1.20)
IIPW with estimated score 0.53 (0.01) 29.16 (0.25) 55.31 (1.15)
IIPW with estimated score, corrected variance 0.53 (0.01) 29.16 (0.15) 55.31 (1.15)
IPS analysis 0.52 (0.01) 28.94 (0.25) 55.71 (1.25)






Education 0.60 (0.01) 30.82 (0.25) 51.24 (0.67)
Smoking 0.59 (0.01) 30.48 (0.24) 52.02 (0.70)
Age group 0.54 (0.01) 29.48 (0.16) 54.72 (0.80)
Education+smoking 0.60 (0.01) 30.76 (0.25) 51.42 (0.68)
Education+age group 0.54 (0.01) 29.50 (0.17) 54.66 (0.80)
Smoking+age group 0.54 (0.01) 29.48 (0.16) 54.84 (0.80)
Education+smoking+age group 0.54 (0.01) 29.54 (0.17) 54.58 (0.79)
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Table 4.2. Causal effect estimates (SE) by smoking status from LRC-CPPT; outcome is the
treatment received for δˆITT, and drop in cholesterol (mg/dL) for ΥˆITT and ΥˆCACE.
Smoking
Non-smoker Smoker
(N = 904) (N = 2880)
δˆITT,j 0.56 (0.02) 0.51 (0.01)
ΥˆITT,j 30.96 (1.66) 25.62 (0.91)
ΥˆCACE,j 55.06(2.68) 50.29 (1.74)
Table 4.3. Interpolated causal effect (SE) based on the distribution of smoking status and
age in NHANES. Outcome is treatment received for δˆITT and drop in cholesterol (mg/dL)












Post-stratification, J = 4 0.53 (0.01) 28.33 (0.91) 53.14 (1.43)
Post-stratification, J = 10 0.53 (0.01) 28.27 (0.93) 53.16 (2.19)
Post-stratification, J = 20 0.53 (0.01) 28.29 (0.94) 53.08 (2.82)
IIPW 0.54 (0.01) 28.15 (0.79) 52.57 (1.42)
IPS 0.53 (0.01) 28.01 (0.87) 52.46 (1.43)
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Table 4.4. Causal effect estimates (SE) by stratum from the New York School Choice
Experiment; the outcome is actual attendance of private school for δˆITT, and change in
grade-normed national centile ranking for ΥˆITT and ΥˆCACE.
Male (n = 349) Female (n = 366)
Reading Math Reading Math
δˆITT,j 0.75 (0.03) 0.73 (0.04)
ΥˆITT,j 4.81 (1.98) 0.46 (2.21) 0.84 (1.81) 5.66 (2.12)
ΥˆCACE,j 6.42 (2.64) 0.61 (2.95) 1.16 (2.48) 7.78 (2.94)
Non-black (n = 365) Black (n = 350)
Reading Math Reading Math
δˆITT,j 0.67 (0.04) 0.81 (0.03)
ΥˆITT,j 2.22 (1.90) 0.35 (2.27) 4.01 (1.85) 6.20 (2.03)
ΥˆCACE,j 3.32 (2.82) 0.52 (3.40) 4.96 (2.30) 7.67 (2.54)
62
Table 4.5. Interpolated results (SE) from the New York School Choice Experiment; the
outcome is actual attendance of private school for δˆITT, and change in grade-normed national
centile ranking for ΥˆITT and ΥˆCACE.
Reading











Sex NYC 2000 Census 0.74 (0.03) 2.87 (1.34) 3.88 (2.56)
US 2000 Census 0.74 (0.03) 2.88 (1.34) 3.89 (2.55)
Race NYC 2000 Census 0.71 (0.03) 2.76 (1.44) 3.88 (2.54)
US 2000 Census 0.69 (0.03) 2.50 (1.63) 3.62 (2.56)
Race & sex NYC 2000 Census 0.71 (0.03) 2.89 (1.44) 4.07 (2.49)
US 2000 Census 0.69 (0.03) 2.70 (1.64) 3.89 (2.48)
Math











Sex NYC 2000 Census 0.74 (0.03) 3.01 (1.53) 4.07 (2.87)
US 2000 Census 0.74 (0.03) 3.01 (1.53) 4.07 (2.81)
Race NYC 2000 Census 0.71 (0.03) 2.10 (1.70) 2.95 (2.83)
US 2000 Census 0.69 (0.03) 1.26 (1.94) 1.82 (2.85)
Race & sex NYC 2000 Census 0.71 (0.03) 1.67 (1.72) 2.35 (2.84)




In this dissertation, we have proposed a rule-based phase I dose-finding design for oncol-
ogy studies. In addition, we have projected the treatment effects from a randomized clinical
trial to a target population. One innovation aspect of this project is interpolation in medical
trials considering compliance.
In Chapter 2, the proposed design is flexible based on the target toxicity probability; it
is more efficient on dose assignment so that more patients can be treated near the potential
maximum tolerated dose, which will be recommended for future trials; and the design is
simple to use. We have developed a package in R to make it more accessible.
The design is targeted for phase I oncology trials in which the toxicity increases with
increasing doses. The aim is to obtain preliminary information on safety fast with few number
of patients. In cases where treatments do not have monotonic dose toxicity relationship, other
designs are better suited.
Rule-based designs use information from patients treated at the maximum tolerated dose
only, whereas model-based designs uses information from all patients to identify a dose that
delivers a targeted dose limiting toxicity rate. This is more accurate and efficient; but
it requires a model based on little data to begin with, then conducts analysis after each
response to recommend dose for the next patient. It requires more time from statisticians
and clinicians. Thus, there is still a continuing role for rule-based designs, especially in
institutions where statistical resources are limited.
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After getting preliminary safety and efficacy information from early-stage trials, more
patients are randomized in late-stage trials for estimating the treatment effect. In Chapter 3
and 4, we use results from late-stage clinical trials to project to the target population where
the same treatment can be applied. When we include stratification factors that show strong
interaction on outcome or compliance, the interpolated estimates can differ substantially from
the trial estimates. Post-stratification can work with just joint distribution of stratifiers.
Approaches using inclusion probabilities are more flexible and accurate on modeling trial
inclusion, but it requires individual-level data that is rarely available for medical trials. In
addition, these approaches require additional step for getting the standard error of estimates
accounting for heterogeneity of causal effect by covariates, which is automatically built-in
for post-stratification.
To conduct interpolation, the patients in the trial are similar to those in the target pop-
ulation, other than on a set of measured covariates. A future direction for this research is
to combine information from similar trials to include a larger group of subjects for interpo-
lation. One example would be to combine information from other trials on cholestyramine
that includes females, so that the target population can include male and female patients.
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APPENDIX A
APPENDIX OF CHAPTER 3
A.1. Appendix A. Equivalence of IPW and post-stratification with discrete S
Define Yij, i = 1, . . . nj, j = 1, . . . J , to be the outcome from subject i in stratum j of the
trial sample. Let nj and Nj represent the total numbers of subjects in stratum j in the trial
and target populations, respectively. Thus, n =
∑J
j=1 nj is the trial size; N =
∑J
j=1Nj is































j Nj = N .
Let nj1 and nj0 be the number of patients in stratum j in the experimental and control
arms, respectively. Note that the inverse-inclusion-probability-weighted estimate is a linear







, if Zij = 1,
− Nj/nj∑
k Nknk0/nk
, if Zij = 0.
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, if Zij = 1,
− Nj
Nnj0
, if Zij = 0.
Under equal randomization fractions in each stratum, i.e., nj0/nj = nj1/nj = 1/2 ∀j, the





In practice, the weights in the two approaches will differ slightly due to accidental imbalances
in randomization fractions across strata.
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